Welcome to watch the recording of our second Sebinar! This time we hear about the latest developments in the “next-gen” immunotherapies (post-immune checkpoint blockade) in the form of new therapies targeting the innate immune system. In the panel discussion we address how new immunotherapies can be taken from preclinical findings towards clinical translation. Invited speakers and panelists were Dr Eric Vivier, Dr Maija Hollmén, Dr Juho Jalkanen and senior adviser Harriet Gullstén.
Please find below the recording and the program with timings.
0:00 Welcome to the Sebinar! Jeroen Pouwels, Cancer IO
3:37 Introduction: Why are innate immune cells important for anti-tumor responses? Maija Hollmén, University of Turku & Cancer IO
13:55 A novel anti-CLEVER-1 mAb targeting immunosuppressive macrophages Juho Jalkanen, Faron Pharmaceuticals
25:45 Harnessing innate immunity in cancer therapy and beyond. Prof. Eric Vivier, Aix-Marseille University and at the Public Hospital of Marseille & Scientific Director in Innate Pharma
1:10:50 Q&A and Panel Discussion: From basic discovery to a novel immunotherapy drug. Prof. Vivier, Dr. Hollmén, Dr. Jalkanen, Business Finland representative, Senior Advisor Harriet Gullstén
Session Chair: Jeroen Pouwels, Cancer IO